PISKEL KYLE 4

What Happened

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies (ADPT), received a grant/award of 61,875 shares on 2026-03-04. The reported acquisition price is $0.00 per share (reported value $0 on the Form 4), indicating an equity award rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-04; reported on Form 4 filed 2026-03-06.
• Transaction type/code: A (award/grant); price reported: $0.00 per share.
• Shares acquired: 61,875.
• Shares owned after transaction: not specified in the filing.
• Footnotes/conditions: none disclosed on the submitted Form 4.
• Timeliness: Filing was submitted two days after the transaction date (no indication of a late filing).

Context

• Code A indicates an award/grant (commonly restricted stock units or similar equity compensation). These are compensation-related and not the same as an insider purchase; they do not by themselves indicate a personal cash investment or a directional market bet.
• Vesting schedules, tax withholding, or any sale of vested shares are not detailed in the filing; such details, if applicable, may appear in other company filings or future Form 4s.